Page 2

### A. Amendments to the Specification:

Please add the following immediately after the title of the invention:

CROSS-REFERENCE TO RELATED APPLICATIONS:

This application is the National Stage of International Application No. PCT/DE2005/000098, filed January 26, 2005, which claims the benefit of German Application No. DE 10 2004 004 122 9, filed January 28, 2004.

Please add the following new paragraph immediately prior to page 1, line 3, and after the Cross Reference to Related Applications, as follows:

FIELD OF THE INVENTION:

Please add the following new paragraph immediately prior to page 1, line 6, as follows:

BACKGROUND OF THE INVENTION:

Please add the following new paragraph immediately prior to page 2, line 39, as follows:

SUMMARY OF THE INVENTION:

Please add the following new paragraph immediately prior to page 3, line 4, as follows:

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS:

Page 3

### Please amend the paragraph at page 14, line 27, as follows:

Example 1.1 1.0 g of the commercial sulfamerazine form 1 (Figure 1.1-a) was ground under normal atmosphere at 800 rpm for 1 hour. Virtually full conversion of form 1 to the desired form 2 was obtained; see Figure 1.1-b.

### Please amend the paragraph at page 14, line 32, as follows:

Example 1.2 1.0 g of the commercial sulfamerazine form 1 (Figure 1.2 a) was ground under normal atmosphere at 800 rpm for 5 minutes. The diffractogram of the analyzed sample exhibits significantly broadened reflections which are, however, still attributable to form 1; see Figure 1.2 b.

### Please amend the paragraph at page 14, line 38, as follows:

Example 1.3 1.0 g of the commercial sulfamerazine form 1 was ground under normal atmosphere at 800 rpm for 15 minutes. The diffractogram of the analyzed sample exhibits very broad reflections which indicate an increased content of amorphous fractions. However, the reflections observed are still attributable to form 1.

#### Please amend the paragraph at page 15, line 5, as follows:

Example 1.4 1.0 g of the commercial sulfamerazine form 1 (Figure 1.3-a) was ground under normal atmosphere at 800 rpm for 30 min minutes. The diffractogram of the analyzed sample exhibits very narrow reflections, all of which are attributable to form 2; see Figure 1.3-b.

Page 4

### Please amend the paragraph at page 15, line 16, as follows:

Example 1.5 10.0 g of the commercial sulfamerazine form 1 were ground under normal atmosphere at 800 rpm for 15 minutes. The diffractogram of the analyzed sample exhibits very broad reflections which indicate an increased content of amorphous fractions. The reflections observed are those of form 1.

### Please amend the paragraph at page 15, line 22, as follows:

Example 1.6 10.0 g of the commercial sulfamerazine form 1 were ground under normal atmosphere at 800 rpm for 30 min minutes. The diffractogram of the analyzed sample exhibits very narrow reflections, all of which are attributable to form 2; see Figure 1.4.

### Please amend the paragraph at page 15, line 27, as follows:

Example 1.7 15.0 g of the commercial sulfamerazine form 1 were ground under normal atmosphere with 2 balls at 800 rpm for 120 and 180 min minutes. The diffractogram of the analyzed sample shows the formation of form 2.

#### Please amend the paragraph at page 16, line 33, as follows:

Experiment 2.1 1.0 g of polymorph 2 of acetazolamide (Figure 2.1-a) was subjected to the process at 800 rpm for 1 hour. The acetazolamide converted virtually fully to polymorph 1 was isolated, see Figure 2.1 c.

#### Please amend the paragraph at page 16, line 38, as follows:

Experiment 2.2 1.0 g of polymorph 2 of acetazolamide (Figure 2.1-a) was subjected to the process at 800 rpm for 5 minutes. The diffractogram of the analyzed sample exhibits very broad

Page 5

reflections which indicate an increased content of amorphous fractions. The reflections observed are attributable to the polymorph 2 used; see Figure 2.2 b.

# Please amend the paragraph at page 17, line 6, as follows:

Experiment 2.3 As Experiment 2.2, except that the acetazolamide was subjected to the process at 800 rpm for 30 minutes. At a treatment time of 30 min, polymorph 1 is isolated; see Figure 2.2 b; Figure 2.2 a before grinding (polymorph 2).

### Please amend the paragraph at page 17, line 11, as follows:

Experiment 2.4 As Experiment 2.2, except that the acetazolamide was subjected to the process at 800 rpm for 45 minutes. At this treatment time, polymorph 1 is likewise isolated, but the reflections observed here are somewhat narrower than at a treatment time of 30 min.

#### Please amend the paragraph at page 17, line 16, as follows:

Experiment 2.5 1.0 g of polymorph 2 of acetazolamide (Figure 2.3 a) was subjected to the process at 400 rpm for 30 minutes. The diffractogram of the analyzed sample exhibits very broad reflections which indicate an increased content of amorphous fractions. The reflections observed are attributable to the polymorph 2 used; see Figure 2.3 b.

#### Please amend the paragraph at page 17, line 23, as follows:

Experiment 2.6 As Experiment 2.5, except that the acetazolamide was subjected to the process at 400 rpm for 60 minutes. Under these conditions too, no phase transformation is observed.

Page 6

### Please amend the paragraph at page 18, line 14, as follows:

Experiment 3.1 Chlorpropamide form A (Figure 3.1-a) was treated under the conditions listed over a period of 1 hour. In addition to a significant broadening of the reflections, partial transformation to form C can be observed; see Figure 3.1-b.

# Please amend the paragraph at page 18, line 19, as follows:

Experiment 3.2 Chlorpropamide form C (Figure 3.2 a) was ground under the conditions listed over a period of 15 minutes. In addition to a significant broadening of the reflections, a clearly perceptible incipient transformation to form A can be observed; see Figure 3.2 b.

# Please amend the paragraph at page 18, line 25, as follows:

Experiment 3.3 Chlorpropamide form C (Figure 3.3-a) was ground under the conditions listed over a period of 60 minutes. The sample has been transformed fully to form A; see Figure 3.3-b.

Please amend the section description for the claims on the top of page 19, as follows: WHAT IS CLAIMED IS: Claims

Please amend the section description for the claims on the top of page 21, as follows: Abstract ABSTRACT OF THE DISCLOSURE: